首页 | 本学科首页   官方微博 | 高级检索  
检索        


Comparative analysis of two methods to detect donor-specific anti-HLA antibodies after kidney transplant
Institution:1. Service of Immunology, Hospital de Clínicas de Porto Alegre, Brazil;2. Service of Nephrology, Hospital de Clínicas de Porto Alegre, Brazil;3. Graduate Program in Medicine: Surgical Sciences, UFRGS, Brazil;4. Graduate Program in Medicine: Medical Sciences, UFRGS, Brazil;1. Transplantation Center of the 3rd Xiangya Hospital, Central South University, Changsha, Hunan 410013, People''s Republic of China;2. Engineering & Technology Research Center for Transplantation Medicine of the National Ministry of Health, Changsha, Hunan 410013, People''s Republic of China;3. Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, People''s Republic of China
Abstract:Preformed anti-human leukocyte antigen (HLA) antibodies may be present in the blood of kidney transplant candidates. The production of these antibodies may occur in the post-transplant period, with the possible development of donor-specific antibodies (DSA). Luminex-based tests, such as the single antigen (SA) assay and the Luminex crossmatch (Xm-DSA) assay are the most commonly used tools to detect anti-HLA antibodies, due to their high sensitivity and specificity. This cross-sectional study aimed to compare the findings of two methods for the detection of DSAs after kidney transplant: SA and Xm-DSA. A total of 122 patients who underwent deceased donor kidney transplant at Hospital de Clínicas de Porto Alegre were included. The SA assay detected anti-class I HLA DSAs in 17 patients (13.9%) and anti-class II HLA DSAs in 22 patients (19.6%), whereas the Xm-DSA detected DSAs in 18 patients (14.8%) both against class I and class II antigens. There was agreement between the two methods for class I (kappa = 0.66, p = 0.001) and class II (kappa = 0.54, p = 0.025) antigens. The incidence of DSAs as obtained by the SA assay was 15.57%, and the most prevalent DSAs were those against HLA-DR antigens. Patient survival at 3 years was 92%. The two techniques assessed in this study provide important information on the presence of DSAs and may help in the post-transplant patient monitoring and in immunosuppressive strategy.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号